The Phase II DORA study, published in April 2024, evaluated the efficacy of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer (aTNBC). In this trial, patients who responded to platinum-based chemotherapy were randomized to receive olaparib alone or in combination with durvalumab. Results showed that progression-free survival (PFS) was longer than historical controls, with a median PFS of 4.0 months for olaparib alone and 6.1 months with the combination. The study demonstrated that a subset of patients, regardless of BRCA mutation or PD-L1 status, achieved durable disease control, particularly those with a prior strong response to platinum therapy. Led by Dr. Tira J. Tan and her team, this research supports further exploration of targeted maintenance strategies in aTNBC.
Read more: https://lnkd.in/e8SR9q4s
